Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ImmunityBio stock in Canada

Learn how to buy ImmunityBio stock in 5 easy steps.

ImmunityBio is a biotechnology business based in the US. ImmunityBio stocks (IBRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.75 – an increase of 15.55% over the previous week. ImmunityBio employs 703 staff and has a trailing 12-month revenue of around $586,000.

How to buy ImmunityBio stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IBRX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

ImmunityBio stock price (NASDAQ:IBRX)

Use our graph to track the performance of IBRX stocks over time.

ImmunityBio shares at a glance

Information last updated 2023-05-26.
Latest market close$2.75
52-week range$1.21 - $7.80
50-day moving average $2.55
200-day moving average $4.11
Wall St. target price$4.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.90

Buy Immunitybio stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy ImmunityBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

ImmunityBio price performance over time

Historical closes compared with the close of $2.75 from 2023-05-31

1 week (2023-05-26) 8.27%
1 month (2023-05-02) -10.71%
3 months (2023-03-02) 35.47%
6 months (2022-12-02) -55.86%
1 year (2022-06-02) -17.66%
2 years (2021-06-02) -84.22%
3 years (2020-05-29) N/A
5 years (2018-05-29) N/A
[/expander_content] [/expander]

ImmunityBio financials

Revenue TTM $586,000
Gross profit TTM $240,000
Return on assets TTM -62.46%
Return on equity TTM 0%
Profit margin 0%
Book value $-1.21
Market capitalisation $1.1 billion

TTM: trailing 12 months

ImmunityBio share dividends

We're not expecting ImmunityBio to pay a dividend over the next 12 months.

ImmunityBio share price volatility

Over the last 12 months, ImmunityBio's shares have ranged in value from as little as $1.21 up to $7.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunityBio's is -0.3371. This would suggest that ImmunityBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ImmunityBio has bucked the trend.

ImmunityBio overview

ImmunityBio, Inc. , a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc. ; and license agreements with LadRx Corporation, GlobeImmune, Inc. , Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site